FSSAI suspends Dior Pharmaceuticals’ nutraceutical manufacturing licence

What to watch

• FSSAI inspection report details, including whether deficiencies are procedural, facility-wide or linked to specific products or batches.
• Any FSSAI recall notice, public safety advisory, product sampling result, fine or prosecution action.
• Timeline for corrective-action submission, reinspection and formal licence reinstatement.
• Evidence of stock-outs, order cancellations, distributor inventory buildup or removal from online and pharmacy listings.
• Use of contract manufacturers, alternate-plant approvals or relaunch of affected products.
• Competitor promotional activity and shelf-space gains in Dior's affected nutraceutical segments.
• Consumer complaints, adverse-event reports, social-media attention or retailer confidence deterioration.
• Halt manufacturing and quarantine in-process materials, finished goods and potentially affected raw-material lots at the Punjab plant.
• Conduct a root-cause audit covering sanitation, GMP documentation, supplier controls, batch records, testing, storage and product traceability.
• Submit a time-bound corrective and preventive action plan to FSSAI and seek reinspection after remediation.
• Assess whether any distributed batches require voluntary withdrawal, market testing or retailer notification.
• Shift eligible production to compliant third-party manufacturers or other approved facilities to protect key SKUs, subject to regulatory approvals.
• Increase communication with distributors, pharmacies, e-commerce partners and healthcare practitioners to manage availability and prevent channel speculation.